BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am 2020;29:145-63. [PMID: 32151353 DOI: 10.1016/j.soc.2019.11.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sun H, Dai S, Xu J, Liu L, Yu J, Sun T. Primary Neuroendocrine Tumor of the Breast: Current Understanding and Future Perspectives. Front Oncol 2022;12:848485. [PMID: 35692784 DOI: 10.3389/fonc.2022.848485] [Reference Citation Analysis]
2 Ocak M, Decristoforo C. Theranostic radiopharmacy for the nuclear medicine and molecular imaging. Nuclear Medicine and Molecular Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00066-1] [Reference Citation Analysis]
3 Harris AG, Vinik AI, OʼDorisio TM, OʼDorisio MS. Radioligand Theranostics in the Management of Neuroendocrine Tumors. Pancreas 2020;49:599-603. [PMID: 32433395 DOI: 10.1097/MPA.0000000000001546] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Redfern JS. Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands. PPIJ 2020;8:325-331. [DOI: 10.15406/ppij.2020.08.00313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]